Morgan Stanley
MENS

Morgan Stanley’s Jyong Biotech MENS Stock Holding History

Morgan Stanley’s Portfolio MENS Stock Details MENS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.5K Sell
6,301
-21,812
-78% -$53.4K ﹤0.01% 6856
2025
Q4 		$111K Buy
28,113
+25,242
+879% +$891K ﹤0.01% 6146
2025
Q3 		$113K Buy
+2,871
New +$103K ﹤0.01% 6098

Other funds holding MENS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.32B AUM 51.82% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley's MENS Position: Q1 2026 in Review

Morgan Stanley reduced its Jyong Biotech (MENS) stake by 78% in Q1 2026, selling an estimated $53.4K and leaving 6,301 shares worth $13.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6856.

Morgan Stanley first reported a position in MENS in Q3 2025 and has held it in 3 quarters since. The position peaked at $113K in Q3 2025. 17 funds tracked by Wall St. Rank hold MENS as of Q1 2026.

  • Morgan Stanley held 6,301 shares of Jyong Biotech worth $13.5K as of Q1 2026.
  • Morgan Stanley sold 21,812 Jyong Biotech shares in Q1 2026, an estimated $53.4K.
  • Jyong Biotech made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6856 holding.
  • Morgan Stanley first reported a position in Jyong Biotech in Q3 2025 and has held it in 3 quarters since.
  • Morgan Stanley's Jyong Biotech position peaked at $113K in Q3 2025.
  • 17 funds tracked by Wall St. Rank held Jyong Biotech as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.